Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options Cancer Network The preferred approach, until recently, was that all patients with CLL and deletion 17p should have human leukocyte antigen (HLA) typing performed and donor search initiated at the time of therapy initiation, in anticipation of alloSCT in first CR ... |
